Core Viewpoint - Chengyi Pharmaceutical (603811.SH) is preparing for the approval of its fish oil drug, expected by September 2025, which is why there are no performance data reflected in the company's semi-annual report for 2025 [1] Group 1 - The fish oil raw material is currently in the application preparation stage and has not yet received approval, thus production and sales activities have not commenced [1] - Sales of fish oil formulations are in the招商 (recruitment) phase, with the company actively negotiating with interested partner enterprises [1]

Core Viewpoint - Chengyi Pharmaceutical (603811.SH) is preparing for the approval of its fish oil drug, expected by September 2025, which is why there are no performance data reflected in the company's semi-annual report for 2025 [1] Group 1 - The fish oil raw material is currently in the application preparation stage and has not yet received approval, thus production and sales have not commenced [1] - Sales of fish oil formulations are in the招商 (recruitment) phase, with the company actively negotiating with interested partner enterprises [1]